Advancing Treatments for Post-Traumatic Stress Disorder (PTSD) September 6, 2024

https://www.fda.gov/drugs/news-events-human-drugs/advancing-treatments-post-traumatic-stress-disorder-ptsd-09062024?utm_medium=email&utm_source=govdelivery FDA Announces Open Registration for Public Meeting on Advancing Treatments for Post-Traumatic Stress Disorder On September 6, 2024, FDA will partner with the Reagan-Udall Foundation to host the public meeting, “Advancing Treatments for Post-Traumatic Stress Disorder (PTSD),” in support of the agency’s ongoing focus on understanding medical need for PTSD treatment with the goal of facilitating treatment development. This public meeting, with both virtual and in-person attendance options, will feature a panel discussion with federal partners to explore efforts to accelerate treatment development for PTSD, including psychedelic drug development. This meeting will also provide an opportunity for people with lived PTSD experience, including veterans, family members, and patient advocates; researchers and scientists; and drug developers to provide public comment. Thirty stakeholders will have up to three minutes each to present public comment either virtually or in-person. The deadline to request to present stakeholder comments is 12 PM (ET) on September 3, 2024. Speakers will be notified by September 4. Advancing Treatments for Post-Traumatic Stress Disorder Hybrid Public Meeting: In-Person and Virtual September 6, 2024 | 1-3:30pm (eastern) https://reaganudall.org/news-and-events/events/advancing-treatments-post-traumatic-stress-disorder?utm_medium=email&utm_source=govdelivery